Noninfectious Posterior Uveitis

• FDA approval · 2026-03-11
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  The FDA approved a supplemental application for OZURDEX (dexamethasone intravitreal implant) submitted by Allergan, Inc.

• CLINICAL_TRIALS research · 2026-02-20
  Clinical Trial Update: Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant

  This clinical trial update describes the frequency and intensity of inflammatory relapses in patients with noninfectious posterior uveitis t…

• FDA approval · 2025-04-04
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for Retisert (fluocinolone acetonide) submitted by Bausch & Lomb.

• CLINICAL_TRIALS research · 2024-08-06
  Clinical Trial Update: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis [Phase 4]

  This clinical trial update describes a Phase 4 study of the fluocinolone acetonide intravitreal implant 0.18 mg for chronic noninfectious po…

• FDA approval · 2016-02-05
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  The FDA approved a supplemental application for Ozurdex (dexamethasone) by Allergan, authorizing an expanded indication for the product.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2015-03-30
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for RETISERT (fluocinolone acetonide) submitted by Bausch & Lomb Incorporated, related to the cortic…

• FDA approval · 2014-06-20
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for RETISERT (fluocinolone acetonide) submitted by Bausch & Lomb Incorporated. The action updates th…

• CLINICAL_TRIALS trial_result · 2011-12-08
  Clinical Trial Update: Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants [Phase 2, Phase 3]

  A completed Phase 2/3 trial assessed the safety and efficacy of fluocinolone acetonide intravitreal implants in patients with noninfectious …

• FDA approval · 2010-11-30
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for Retisert (fluocinolone acetonide) submitted by Bausch & Lomb Incorporated. The action approves a…

• FDA label_change · 2010-08-31
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  FDA approved a supplemental application for OZURDEX (dexamethasone) from Allergan, Inc., likely resulting in changes to the product labeling…

• FDA approval · 2007-10-30
  FDA Approved: RETISERT — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for RETISERT, the fluocinolone acetonide implant by Bausch & Lomb. This action pertains to an amendm…